8-K EIRGENIX AMENDMENT

Company

Bolt Biotherapeutics, Inc.

Filed

January 25, 2022

Period of Report

January 25, 2022

Accession Number

0001564590-22-002321

An 8-K is a current report used to announce material events that shareholders should know about — such as earnings releases, mergers, executive changes, or bankruptcy. Learn more about 8-K filings →